Bulk Quote Inquiry

MHC-HM405B-100μg / Inquiry

MHC-HM405B-500μg / Inquiry

MHC-HM405B-1mg / Inquiry

Biotinylated Human NY-ESO-1 (HLA-A*02:01) Complex Protein

Product Info
Source

Recombinant Biotinylated Human NY-ESO-1 (HLA-A*02:01) Complex Protein is expressed from Expi293 with His tag and Avi tag at the C-terminal. It contains Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) and SLLMWITQC peptide.[Accession | P04439&P61769&SLLMWITQC]

Molecular Weight

The protein has a predicted MW of 50.5 kDa.Due to glycosylation, the protein migrates to 51-60 kDa based on Tris-Bis PAGE result.

Endotoxin

Less than 1EU per μg by the LAL method.

Purity

> 95% as determined by Tris-Bis PAGE
> 95% as determined by SEC-HPLC

Formulation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.

Reconstitution

Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage

The product should be stored at -70℃ or -20℃.

Assay Data
Tris-Bis PAGE

Biotinylated Human NY-ESO-1 (HLA-A*02:01) Complex on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

The purity of Biotinylated Human NY-ESO-1 (HLA-A*02:01) Complex was greater than 95% as determined by SEC-HPLC.

ELISA Data

Immobilized Biotinylated Human NY-ESO-1 (HLA-A*02:01) Complex at 5μg/ml (100μl/Well) on the plate. Dose response curve for Anti-NY-ESO-1(HLA-A*02:01) Antibody, hFc Tag with the EC50 of 13.6ng/ml determined by ELISA.

Background

NY-ESO-1 is a human tumor antigen of the cancer/testis family. It is highly expressed in many poor-prognosis melanomas.The Human HLA-A*0201 NY-ESO-1 (SLLMWITQC) complex Protein is a complex of HLA-A*0201 of  the MHC Class I, B2M and SLLMWITQC peptide of  the NY-ESO-1 .

Synonyms

MHC;MY-ESO-1;Cancer/testis antigen 6.1;L antigen family member 2;CT6.1;LAGE-2

References

(1)Donnellan Z , Bossi G , Harper J , et al. ImmTACs: bi-specific TCR-anti-CD3 fusions for targeted tumour killing[J]. Journal for ImmunoTherapy of Cancer, 2015, 3(Suppl 2):P299.

Kactus Biosystems Co.Ltd
Online Message